Peter Houghton

Summary

Affiliation: Nationwide Children's Hospital
Country: USA

Publications

  1. pmc Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2
    Hemant K Bid
    Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, 700 Children s Drive, Columbus, OH 43205, USA
    Mol Cancer Ther 11:649-59. 2012
  2. pmc Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Pediatr Blood Cancer 58:636-9. 2012
  3. pmc Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Center for Children s Cancer, Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Mol Cancer Ther 9:101-12. 2010
  4. pmc Everolimus
    Peter J Houghton
    Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Clin Cancer Res 16:1368-72. 2010
  5. doi request reprint Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 58:191-9. 2012
  6. pmc Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 58:200-9. 2012
  7. doi request reprint Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 57:443-53. 2011
  8. doi request reprint Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice
    Grace Ifeyinwa Onimoe
    Center for Childhood Cancer, The Research Institute at Nationwide Children s Hospital, Columbus, OH, USA
    Invest New Drugs 30:916-26. 2012
  9. doi request reprint mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α
    Hakan Cam
    Center for Childhood Cancer, Nationwide Children s Hospital, Columbus, OH 43205, USA
    Mol Cell 40:509-20. 2010

Research Grants

Collaborators

Detail Information

Publications9

  1. pmc Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2
    Hemant K Bid
    Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, 700 Children s Drive, Columbus, OH 43205, USA
    Mol Cancer Ther 11:649-59. 2012
    ..Many childhood cancers secrete IGF-2, suggesting that tumor-derived IGF-2 in the microenvironment maintains angiogenesis in the presence of IGF-1R-targeted antibodies allowing tumor progression...
  2. pmc Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Pediatr Blood Cancer 58:636-9. 2012
    ..No objective tumor responses were observed. In vivo LCL161 demonstrated limited single agent activity against the pediatric preclinical models studied...
  3. pmc Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Center for Children s Cancer, Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Mol Cancer Ther 9:101-12. 2010
    ....
  4. pmc Everolimus
    Peter J Houghton
    Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Clin Cancer Res 16:1368-72. 2010
    ..Further, biomarkers that predict tumor sensitivity are still elusive. The mechanism of action, preclinical antitumor activity, and clinical activity of everolimus against RCC are reviewed...
  5. doi request reprint Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 58:191-9. 2012
    ..Procedures AZD8055 was tested against the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10 µM and against the PPTP in vivo panels at a dose of 20 mg/kg administered orally daily x 7 for 4 weeks...
  6. pmc Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 58:200-9. 2012
    ..Genz-644282 is a novel non-camptothecin topoisomerase I poison that is in clinical development...
  7. doi request reprint Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 57:443-53. 2011
    ..PR-104 activation can occur via hypoxia-dependent reductases and also independently of hypoxia by aldo-keto reductase (AKR) 1C3...
  8. doi request reprint Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice
    Grace Ifeyinwa Onimoe
    Center for Childhood Cancer, The Research Institute at Nationwide Children s Hospital, Columbus, OH, USA
    Invest New Drugs 30:916-26. 2012
    ..Blocking persistent STAT3 signaling by LLL12 and FLLL32 may be a novel therapeutic approach for osteosarcoma...
  9. doi request reprint mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α
    Hakan Cam
    Center for Childhood Cancer, Nationwide Children s Hospital, Columbus, OH 43205, USA
    Mol Cell 40:509-20. 2010
    ..Deregulation of these pathways in pediatric solid tumor xenografts suggests a link between mTORC1 dysregulation and solid tumor development and points to an important role for hypoxic regulation of mTORC1 activity in tumor development...

Research Grants16

  1. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter J Houghton; Fiscal Year: 2010
    ..The studies have the potential to radically alter outcome for these children, and reduce the debilitating sequellae of high dose radiation and chemotherapy. ..
  2. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2009
    ..The studies have the potential to radically alter outcome for these children, and reduce the debilitating sequellae of high dose radiation and chemotherapy. ..
  3. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2007
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  4. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2005
    ..abstract_text> ..
  5. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 2002
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..